Tramadol Hydrochloride
Product Images NDC 68071-2648

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 68071-2648). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2648 3)

Label for Tramadol Hydrochloride 100 mg extended-release tablets by NuCare Pharmaceuticals, Inc. The package contains 30 tablets and is marked as a Schedule IV controlled substance. It includes NDC 68071-2648-3 and states 'Rx Only.' Manufacturer details list Sun Pharmaceutical Industries Ltd, Mumbai, India, and NuCare Pharmaceuticals, Inc., Orange, CA. The label advises to see the manufacturer's label for full ingredients and storage at controlled temperature 68-77°F.*

FDA Label Image

Tramadol-figure1 (Tramadol Figure1)

A pharmacokinetic line graph comparing plasma concentration over 24 hours of Tramadol Hydrochloride Extended-Release Tablets 200 mg once daily and Tramadol IR Tablets 50 mg every six hours (q6h). The y-axis displays Tramadol concentration in ng/mL, and the x-axis shows time in hours.*

FDA Label Image

Tramadol-figure2 (Tramadol Figure2)

A line graph comparing M1 concentration (ng/mL) over 24 hours between Tramadol Hydrochloride Extended-Release Tablets (200 mg once daily) and Tramadol IR Tablets (50 mg every 6 hours). The graph shows two curves representing the concentration levels across time.*

FDA Label Image

Tramadol-figure3 (Tramadol Figure3)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 023 WOMAC Pain Responder Analysis' depicting the percent of patients achieving various response thresholds. The x-axis shows Response Threshold (Percent Improvement from Baseline) from 0 to 100%, and the y-axis shows Percent of Patients Achieving Response from 0 to 60%. Five lines represent different doses of tramadol hydrochloride extended-release tablets (100 mg, 200 mg, 300 mg, 400 mg) and a placebo, illustrating patient response at multiple thresholds.*

FDA Label Image

Tramadol-figure4 (Tramadol Figure4)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 015 Arthritis Pain Intensity VAS Responder Analysis' showing percent of patients achieving response against response threshold (percent improvement from baseline). Two lines compare Tramadol Hydrochloride Extended-Release Tablets to Placebo, displaying higher response rates for the Tramadol group across thresholds.*

FDA Label Image

Tramadol-structure (Tramadol Structure)

Chemical structure of tramadol hydrochloride, showing its molecular arrangement including a cyclohexane ring, hydroxyl group, methoxybenzene, and dimethylamine linked to a hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.